[144] Arcutis Biotherapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 filed for Arcutis Biotherapeutics, Inc. (ARQT) discloses a proposed sale of 1,750 common shares through Merrill Lynch on 08/19/2025. The shares were acquired by restricted stock vesting on 08/18/2025. The filer lists four recent sales by Patrick Burnett within the past three months totaling 33,219 shares for aggregate gross proceeds of $521,160.00 (sales on 07/10/2025, 07/14/2025, 08/04/2025, and 08/08/2025). The notice affirms the filer is not aware of undisclosed material adverse information and includes the standard attestation about trading plans and criminal penalties for misstatement.

Positive

• Disclosure compliance: The filing includes required Rule 144 details (broker, amounts, dates), supporting regulatory transparency
• Attestation provided: The signer certifies no undisclosed material adverse information

Negative

• Insider selling activity: Recent sales total 33,219 shares for about $521,160, which may be viewed negatively by some investors
• Rapid disposition of vested shares: Restricted stock vested on 08/18/2025 and the proposed sale is scheduled for 08/19/2025

Insights

Securities Analyst

TL;DR: Insider sales totaling 33,219 shares recently and a proposed 1,750-share sale are disclosed; impact appears routine and procedural.

The filing shows an insider receipt of restricted stock on 08/18/2025 followed by a planned sale the next day, which is typical for holders monetizing vested awards. Recent disclosed sales by Patrick Burnett amount to 33,219 shares for approximately $521,160 in proceeds, indicating active insider liquidity but not necessarily reflecting company fundamentals. The disclosure follows Rule 144 procedural requirements and provides transparent broker and transaction timing details.

Corporate Governance Expert

TL;DR: Disclosure is compliant with Rule 144 and includes the required attestation; multiple recent insider sales warrant routine governance monitoring.

The Form 144 includes necessary seller identity, broker (Merrill Lynch), share counts, and dates, satisfying disclosure norms. The proximity of vesting (08/18/2025) to the proposed sale (08/19/2025) suggests prompt disposition of vested awards. While not indicative of misconduct, governance teams and investors often track the cadence and scale of insider dispositions to assess alignment with shareholder interests.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 8890 Lyra Dr. 5th Floor Columbus OH 43240	1750	28228.00	119905078	08/19/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/18/2025	Restricted stock vest	Arcutis Biotherapetics Inc			1750	08/19/2025	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Patrick Burnett 3027 Townsgate Rd Ste 300 Westlake Village CA 91361	common	08/08/2025	3847	53873.00
Patrick Burnett 3027 Townsgate Rd Ste 300 Westlake Village CA 91361	Common	07/10/2025	23000	346047.00
Patrick Burnett 3027 Townsgate Rd Ste 300 Westlake Village CA 91361	Common	07/14/2025	5750	86654.00
Patrick Burnett 3027 Townsgate Rd Ste 300, Westlake Village CA 91361	Common	08/04/2025	2622	37486.00

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What shares does the ARQT Form 144 propose to sell?

The notice proposes sale of 1,750 common shares via Merrill Lynch on 08/19/2025.

When were the shares to be sold acquired?

The 1,750 shares were acquired by restricted stock vesting on 08/18/2025 from Arcutis Biotherapeutics, Inc.

How many shares has the filer sold in the past three months?

The filing discloses four sales by Patrick Burnett totaling 33,219 shares for aggregate gross proceeds of $521,160.00.

Through which broker will the proposed sale occur?

The proposed sale is listed through Merrill Lynch (address: 8890 Lyra Dr. 5th Floor, Columbus, OH).

Does the filer assert any undisclosed material information?

The filer represents by signature that they do not know any material adverse information about the issuer that has not been publicly disclosed.